Regulus Therapeutics Files 2024 Annual Report Amendment
| Field | Detail |
|---|---|
| Company | Regulus Therapeutics Inc. |
| Form Type | 10-K/A |
| Filed Date | Apr 30, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceutical
TL;DR
Regulus Therapeutics filed its amended 2024 10-K on 4/30/25. Check for updates.
AI Summary
Regulus Therapeutics Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 30, 2025, provides updated information for the company, which is incorporated in Delaware and headquartered in San Diego, CA.
Why It Matters
This amendment to the annual report provides updated financial and operational information for Regulus Therapeutics Inc., which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Regulus Therapeutics is subject to inherent risks related to drug development, clinical trials, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the annual report.)
- 2025-04-30 — Filing Date (The date the amendment was submitted to the SEC.)
Key Players & Entities
- Regulus Therapeutics Inc. (company) — Registrant
- 2024-12-31 (date) — Fiscal Year End
- 2025-04-30 (date) — Filing Date
- San Diego, CA (location) — Company Headquarters
- Delaware (location) — State of Incorporation
FAQ
What specific information was updated in this 10-K/A filing?
The filing is an amendment to the annual report for the fiscal year ended December 31, 2024, indicating that updates or corrections were made to the original 10-K.
What is the primary business of Regulus Therapeutics Inc.?
Regulus Therapeutics Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
When was the original 10-K filed for the fiscal year ending December 31, 2024?
While the amendment date is April 30, 2025, the original 10-K filing date for the fiscal year ended December 31, 2024, is not explicitly stated in this header information, but it would have preceded this amendment.
Where is Regulus Therapeutics Inc. located?
The company's business and mailing address is 4224 Campus Point Court, Suite 210, San Diego, CA 92121.
What is the SEC file number for Regulus Therapeutics Inc.?
The SEC file number for Regulus Therapeutics Inc. is 001-35670.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding Regulus Therapeutics Inc..